Physician profile
Mindy E Meyer
NPI 1639495716
$2,708.88
in general payments reported to CMS, 2019-2025
26 companies · $573 in 2025
The $573 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $257 · 2023: $714 · 2024: $801 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $726.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $299.61 | 2024-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $260.65 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $213.54 | 2021-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $179.24 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Dexcom, INC. | $147.74 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Pfizer INC. | $119.49 | 2021-2025 | |
| Heartflow, INC. | $112.27 | 2023 | Ffrct |
| Astellas Pharma US INC | $82.61 | 2021-2024 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $73.74 | 2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $65.93 | 2023 | Inspire |
| Jazz Pharmaceuticals INC. | $55.62 | 2021-2022 | |
| Lundbeck LLC | $55.17 | 2021-2023 | Vyepti |
| Vbi Vaccine (Delaware) INC. | $46.56 | 2022-2023 | Prehevbrio |
| Nevro Corp. | $34.90 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $34.83 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.72 | 2023-2025 | Ofev, Jardiance |
| Medtronic, INC. | $29.08 | 2022-2024 | Intellis Adaptivestim |
| Tris Pharma INC | $28.21 | 2023-2025 | Dyanavel Xr |
| Ars Pharmaceuticals Operations, INC. | $18.86 | 2025 | Neffy |
| Daiichi Sankyo INC. | $18.23 | 2024 | Injectafer |
| Idorsia Pharmaceuticals US INC | $15.86 | 2023 | Quviviq |
| Boston Scientific Corporation | $14.68 | 2024 | |
| Dynavax Technologies Corporation | $14.61 | 2024 | Heplisav-B |
| Takeda Pharmaceuticals U.S.A., INC. | $14.07 | 2022 | |
| Exact Sciences Corporation | $13.51 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.